Search

Your search keyword '"Emmanuel Bachy"' showing total 6 results
Start Over Author "Emmanuel Bachy" Journal bulletin du cancer
6 results on '"Emmanuel Bachy"'

2. CAR-T cell: Toxicities issues: Mechanisms and clinical management

Author

Florent, Wallet, Pierre, Sesques, Perrine, Devic, Melanie, Levrard, Florence, Ader, Arnaud, Friggeri, and Emmanuel, Bachy

Subjects
Cancer Research, Receptors, Chimeric Antigen, T-Lymphocytes, Hematology, General Medicine, Antibodies, Monoclonal, Humanized, Infections, Immunotherapy, Adoptive, Oncology, Adrenal Cortex Hormones, Agammaglobulinemia, Risk Factors, Humans, Neurotoxicity Syndromes, Radiology, Nuclear Medicine and imaging, Cytokine Release Syndrome, Biomarkers
Abstract

CAR-T cells are modified T cells expressing a chimeric antigen receptor targeting a specific antigen. They have revolutionized the treatment of B cell malignancies (aggressive lymphomas, B-ALL), and this has raised hopes for application in many other pathologies (myeloma, AML, solid tumors, etc.). However, these therapies are associated with novel and specific toxicities (cytokine release syndrome and neurotoxicity). These complications, although mostly managed in a conventional hospitalization unit, can sometimes be life threatening, leading to admission of patients to the intensive care unit. Management relies mainly on anti-IL6R (tocilizumab) and corticosteroids. However, the optimal treatment regimen is still a matter of debate, and the management of the most severe forms is even less well codified. In addition to CRS and ICANS, infections, cytopenia and hypogammaglobulinemia are other frequent complications. This article reviews the mechanisms, risk factors, clinical presentation, and management of these toxicities.

Published
2021

3. CAR-T cells, from principle to clinical applications

Author

Estelle Bourbon, Hervé Ghesquières, and Emmanuel Bachy

Subjects
Cancer Research, T-Lymphocytes, Antigens, CD19, History, 18th Century, Immunotherapy, Adoptive, Lymphocyte Depletion, Lymphocytes, Tumor-Infiltrating, Antibody Specificity, Neoplasms, Humans, Radiology, Nuclear Medicine and imaging, Israel, Carcinoma, Renal Cell, Lymphoma, Follicular, Ovarian Neoplasms, Clinical Trials as Topic, Receptors, Chimeric Antigen, History, 19th Century, Hematology, General Medicine, History, 20th Century, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Kidney Neoplasms, United States, Europe, Oncology, Female, Multiple Myeloma
Abstract

Chimeric antigen receptors (CAR)-T cells are genetically engineered T-lymphocytes redirected with a predefined specificity to any target antigen, in a non-HLA restricted manner, therefore combining antibody-type specificity with effector T-cell function. This strategy was developed some thirty years ago, after extensive work established the key role of the immune system against cancer. The first-engineered T-cell with chimeric molecule was designed in 1993 by Israeli immunologist Zelig Eshhar. Since then, several modifications took place, including the addition of co-stimulatory domain, to further improve CAR-T cell anti-tumor potency. The first clinical application of CAR-T cell was done in Rotterdam in 2005 for metastatic renal cell carcinoma and simultaneously at the National Cancer Institute (NCI) for metastatic ovarian cancer. These pioneered studies failed to demonstrate a therapeutic benefit, but warning emerged concerning their safety of use. The real clinical success came with anti-CD19 CAR-T cells, used since 2009 by Steven Rosenberg at the NCI in a patient with refractory follicular lymphoma and in 2011 by Carl June and David Porter from the University of Pennsylvania in patients with chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia. From that time, large centers in North America have embarked in several early phase and pivotal trials that have demonstrated unprecedent response rate in heavily pretreated chemo refractory patient with B-cell malignancies. Theses clinical success have led to the approval of three anti-CD19 CAR-T cells products for the management of B-cell malignancies in the United States and in Europe as of December 2020.

Published
2021

4. Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC

Author

Franck Morschhauser, Florence Rabian, Catherine Thieblemont, Marie-Thérèse Rubio, Guillaume Cartron, David Beauvais, Steven Le Gouill, Jacques-Olivier Bay, André Baruchel, Sabine Furst, Gandhi Damaj, Denis Caillot, Emmanuel Bachy, Ibrahim Yakoub-Agha, Université de Lille, Hôpital Claude Huriez [Lille], CHU Lille, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Recherche clinique appliquée à l'hématologie (URP_3518), Université de Paris (UP), Hôpital Robert Debré, CHU Clermont-Ferrand, CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Caen Normandie (UNICAEN), Normandie Université (NU), Institut d'Hématologie de Basse-Normandie (IHBN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine, ex- Institut Universitaire Hématologie-IUH) (IRSL), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université Paris Diderot - Paris 7 (UPD7), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Paris Cité (UPCité), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), and Bernardo, Elizabeth

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, CAR T-cells, Leucémie aiguë lymphoblastique B, Lymphoblastic Leukemia, [SDV.CAN]Life Sciences [q-bio]/Cancer, Marketing authorization, B-cell acute lymphoblastic leukemia, CD19, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, hemic and lymphatic diseases, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Lymphome diffus à grandes cellules B, biology, business.industry, Diffuse large B-cell lymphoma, Hematology, General Medicine, medicine.disease, Tumor antigen, Chimeric antigen receptor, 3. Good health, Lymphoma, Cellules CAR-T, 030104 developmental biology, Anticancer treatment, 030220 oncology & carcinogenesis, Expert opinion, biology.protein, business
Abstract

International audience; The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (KymriahTM) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (YescartaTM) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologous T-cells directed against CD19. This collaborative work, part of a series of expert opinion-based work, aims to give practical advice to help centers in selection of patients for commercially available CAR T-cell treatment.

Published
2021

6. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]

Author

David, Beauvais, Emmanuel, Bachy, André, Baruchel, Jacques-Olivier, Bay, Denis, Caillot, Guillaume, Cartron, Gandhi, Damaj, Sabine, Furst, Steven, Le Gouill, Franck, Morschhauser, Florence, Rabian, Marie-Thérèse, Rubio, Catherine, Thieblemont, and Ibrahim, Yakoub-Agha

Subjects
Biological Products, Receptors, Chimeric Antigen, Substance-Related Disorders, Patient Selection, Antigens, CD19, Receptors, Antigen, T-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Immunotherapy, Adoptive, Mediastinal Neoplasms, Europe, Young Adult, Humans, Lymphoma, Large B-Cell, Diffuse, Child
Abstract

The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (Kymriah

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results